Us Fda approves Lilly migraine drug; price same as rivals

Us Fda approves Lilly migraine drug; price same as rivals


NEW YORK: Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches. Lilly said it plans to sell the drug, known chemically as galcanezumab, at a list price of US$6,900 a year, or US$575 month.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога